CD8A and neoplasm: However, a preclinical study revealed that the treatment with anti-mouse TNFR2 surrogate antibody (suAb) abrogated TNF-induced expansion of Tregs in vitro and decreased expression of PD-1 on CD8 tumor-infiltrating lymphocytes (TILs) in vivo (46).